Targeting protein geranylgeranylation slows tumor development in a murine model of prostate cancer metastasis

References

• Pirtskhalaishvili G, Hrebinko RL, Nelson JB. The treatment of prostate cancer: an overview of current options. Cancer Pract 2001; 9(6):295-306; PMID:11879332; http://dx.doi.org/10.1046/j.1523-5394.2001.96009.x
   PubMedGoogle Scholar
• Mettlin C. Changes in patterns of prostate cancer care in the United States: results of American College of Surgeons Commission on Cancer studies, 1974–1993. Prostate 1997; 32(3):221-6; PMID:9254902; http://dx.doi.org/10.1002/(SICI)1097-0045(19970801)32:3%3c221::AID-PROS9%3e3.0.CO;2-N
   PubMed Web of Science ®Google Scholar
• Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 1998; 160(4):1220-9; PMID:9751323; http://dx.doi.org/10.1016/S0022-5347(01)62501-1
   PubMed Web of Science ®Google Scholar
• O'Brien LE, Jou TS, Pollack AL, Zhang QH, Hansen SH, Yurchenco P, Mostov KE. Rac1 orientates epithelial apical polarity through effects on basolateral laminin assembly. Nat Cell Biol 2001; 3(9):831-8; PMID:11533663; http://dx.doi.org/10.1038/ncb0901-831
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Tanaka K, Harimaya K, Nakatani F, Matsuda S, Iwamoto Y. Small GTP-binding protein, Rho, both increased and decreased cellular motility, activation of matrix metalloproteinase 2 and invasion of human osteosarcoma cells. Japanese J Cancer Res 2001; 92(4):429-38; PMID:11346466; http://dx.doi.org/10.1111/j.1349-7006.2001.tb01113.x
   PubMedGoogle Scholar
• Worthylake RA, Lemoine S, Watson JM, Burridge K. RhoA is required for monocyte tail retraction during transendothelial migration. J Cell Biol 2001; 154(1):147-60; PMID:11448997; http://dx.doi.org/10.1083/jcb.200103048
   PubMed Web of Science ®Google Scholar
• Braga VMM, Betson M, Li XD, Lamarche-Vane N. Activation of the small GTPase Rac is sufficient to disrupt cadherin-dependent cell-cell adhesion in normal human keratinocytes. Mol Biol Cell 2000; 11(11):3703-21; PMID:11071901; http://dx.doi.org/10.1091/mbc.11.11.3703
   PubMed Web of Science ®Google Scholar
• Braga VMM, Machesky LM, Hall A, Hotchin NA. The small GTPases rho and rac are required for the establishment of cadherin-dependent cell-cell contacts. J Cell Biol 1997; 137(6):1421-31; PMID:9182672; http://dx.doi.org/10.1083/jcb.137.6.1421
   PubMed Web of Science ®Google Scholar
• Quinlan MP. Rac regulates the stability of the adherens junction and its components, thus affecting epithelial cell differentiation and transformation. Oncogene 1999; 18(47):6434-42; PMID:10597245; http://dx.doi.org/10.1038/sj.onc.1203026
   PubMed Web of Science ®Google Scholar
• Zondag GCM, Evers EE, ten Klooster JP, Janssen L, van der Kammen RA, Collard JG. Oncogenic Ras downregulates Rac activity, which leads to increased Rho activity and epithelial-mesenchymal transition. J Cell Biol 2000; 149(4):775-81; PMID:10811819; http://dx.doi.org/10.1083/jcb.149.4.775
   PubMed Web of Science ®Google Scholar
• Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000; 406(6795):532-5; PMID:10952316; http://dx.doi.org/10.1038/35020106
   PubMed Web of Science ®Google Scholar
• Maltese WA. Posttranslational modification of proteins by isoprenoids in mammalian-cells. Faseb J 1990; 4(15):3319-28; PMID:2123808
   PubMed Web of Science ®Google Scholar
• Adamson P, Etienne S, Couraud PO, Calder V, Greenwood J. Lymphocyte migration through brain endothelial cell monolayers involves signaling through endothelial ICAM-1 via a Rho-dependent pathway. J Immunol 1999; 162(5):2964-73
   PubMed Web of Science ®Google Scholar
• Clarke S. Protein isoprenylation and methylation at carboxyl-terminal cysteine residues. Ann Rev Biochem 1992; 61:355-86; PMID:1497315; http://dx.doi.org/10.1146/annurev.bi.61.070192.002035
   PubMed Web of Science ®Google Scholar
• Lyons LS, Rao S, Balkan W, Faysal J, Maiorino CA, Burnstein KL. Ligand-Independent Activation of Androgen Receptors by Rho GTPase Signaling in Prostate Cancer. Mol Endocrinol 2008; 22(3):597-608; PMID:18079321; http://dx.doi.org/10.1210/me.2007-0158
   PubMed Web of Science ®Google Scholar
• Knight-Krajewski S, Welsh CF, Liu Y, Lyons LS, Faysal JM, Yang ES, Burnstein KL. Deregulation of the Rho GTPase, Rac1, suppresses cyclin-dependent kinase inhibitor p21(CIP1) levels in androgen-independent human prostate cancer cells. Oncogene 2004; 23(32):5513-22; PMID:15077174; http://dx.doi.org/10.1038/sj.onc.1207708
   PubMed Web of Science ®Google Scholar
• Engers R, Ziegler S, Mueller M, Walter A, Willers R, Gabbert HE. Prognostic relevance of increased Rac GTPase expression in prostate carcinomas. Endocr Relat Cancer 2007; 14(2):245-56; PMID:17639041; http://dx.doi.org/10.1677/ERC-06-0036
   PubMed Web of Science ®Google Scholar
• Lin K-T, Gong J, Li C-F, Jang T-H, Chen W-L, Chen H-J, Wang L-H. Vav3-Rac1 Signaling Regulates Prostate Cancer Metastasis with Elevated Vav3 Expression Correlating with Prostate Cancer Progression and Posttreatment Recurrence. Cancer Research 2012; 72(12):3000-9; PMID:22659453; http://dx.doi.org/10.1158/0008-5472.CAN-11-2502
   PubMed Web of Science ®Google Scholar
• Qin J, Xie Y, Wang B, Hoshino M, Wolff DW, Zhao J, Scofield MA, Dowd FJ, Lin MF, Tu Y. Upregulation of PIP3-dependent Rac exchanger 1 (P-Rex1) promotes prostate cancer metastasis. Oncogene 2009; 28(16):1853-63; PMID:19305425; http://dx.doi.org/10.1038/onc.2009.30
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Inoue T, Shimizu Y, Terada N, Maeno A, Kajita Y, Yamasaki T, Kamba T, Toda Y, Mikami Y, Yamada T, Kamoto T, Ogawa O, Nakamura E. Activation of Rac1 Is Closely Related to Androgen-Independent Cell Proliferation of Prostate Cancer Cells Both in Vitro and in Vivo. Mol Endocrinol 2010; 24(4):722-34; PMID:20203103; http://dx.doi.org/10.1210/me.2009-0326
   PubMed Web of Science ®Google Scholar
• Suzuki S, Pitchakarn P, Sato S, Shirai T, Takahashi S. Apocynin, an NADPH oxidase inhibitor, suppresses progression of prostate cancer via Rac1 dephosphorylation. Exp Toxicol Pathol 2013; 65(7-8):1035-41; PMID:23664830; http://dx.doi.org/10.1016/j.etp.2013.03.002
   PubMed Web of Science ®Google Scholar
• Hattori M, Minato N. Rap1 GTPase: Functions, regulation, and malignancy. J Biochem 2003; 134(4):479-84; PMID:14607972; http://dx.doi.org/10.1093/jb/mvg180
   PubMed Web of Science ®Google Scholar
• Yajnik V, Paulding C, Sordella R, McClatchey AI, Saito M, Wahrer DCR, Reynolds P, Bell DW, Lake R, van den Heuvel S, Settleman J, Haber DA. DOCK4, a GTPase activator, is disrupted during tumorigenesis. Cell 2003; 112(5):673-84; PMID:12628187; http://dx.doi.org/10.1016/S0092-8674(03)00155-7
   PubMed Web of Science ®Google Scholar
• Zhang LZ, Li CW, Mahmood R, van Golen K, Greenson J, Li GY, D'Silva NJ, Li XQ, Burant CF, Logsdon CD, Simeone DM. Identification of a putative tumor suppressor gene Rap1GAP in pancreatic cancer. Cancer Res 2006; 66(2):898-906; PMID:16424023; http://dx.doi.org/10.1158/0008-5472.CAN-05-3025
   PubMed Web of Science ®Google Scholar
• Gao L, Feng YF, Bowers R, Becker-Hapak M, Gardner J, Council L, Linette G, Zhao HB, Cornelius LA. Ras-associated protein-1 regulates extracellular signal-regulated kinase activation and migration in melanoma cells: Two processes important to melanoma tumorigenesis and metastasis. Cancer Res 2006; 66(16):7880-8; PMID:16912161; http://dx.doi.org/10.1158/0008-5472.CAN-06-0254
   PubMed Web of Science ®Google Scholar
• Crawford NPS, Ziogas A, Peel DJ, Hess J, Anton-Culver H, Hunter KW. Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer. Breast Cancer Res 2006; 8(2); PMID:16563182; http://dx.doi.org/10.1186/bcr1389
   PubMed Web of Science ®Google Scholar
• Bailey CL, Kelly P, Casey PJ. Activation of Rap1 Promotes Prostate Cancer Metastasis. Cancer Res 2009; 69(12):4962-8; PMID:19470770; http://dx.doi.org/10.1158/0008-5472.CAN-08-4269
   PubMed Web of Science ®Google Scholar
• Xiang J, Bian CD, Wang H, Huang SS, Wu DL. MiR-203 down-regulates Rap1A and suppresses cell proliferation, adhesion and invasion in prostate cancer. J Exp Clin Cancer Res 2015; 34; http://dx.doi.org/10.1186/s13046-015-0125-x
   Web of Science ®Google Scholar
• O'Brien LE, Jou TS, Pollack AL, Zhang Q, Hansen SH, Yurchenco P, Mostov KE. Rac1 orientates epithelial apical polarity through effects on basolateral laminin assembly. Nat Cell Biol 2001; 3:831-8; PMID:11533663; http://dx.doi.org/10.1038/ncb0901-831
   PubMed Web of Science ®Google Scholar
• Worthylake RA, Lemoine S, Watson JM, Burridge K. RhoA is required for monocyte tail retraction during transendothelial migration. The J Cell Biol 2001; 154(1):147-160; PMID:11448997; http://dx.doi.org/10.1083/jcb.200103048
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Tanaka K, Harimaya K, Nakatani F, Matsuda S, Iwamoto Y. Small GTP-binding protein, Rho, both increased and decreased cellular motility, activation of matrix metalloproteinase 2 and invasion of human osteosarcoma cells. Jpn J Cancer Res 2001; 92:429–438
   Google Scholar
• Giehl K. Oncogenic Ras in tumour progression and metastasis. Biol Chem 2005; 386(3):193-205; PMID:15843165
   PubMed Web of Science ®Google Scholar
• Faried A, Faried LS, Kimura H, Nakajima M, Sohda M, Miyazaki T, Kato H, Usman N, Kuwano H. RhoA and RhoC proteins promote both cell proliferation and cell invasion of human oesophageal squamous cell carcinoma cell lines in vitro and in vivo. Eur J Cancer 2006; 42(10):1455-65; PMID:16750623; http://dx.doi.org/10.1016/j.ejca.2006.02.012
   PubMed Web of Science ®Google Scholar
• Mack NA, Whalley HJ, Castillo-Lluva S, Malliri A. The diverse roles of Rac signaling in tumorigenesis. Cell Cycle 2011; 10(10):1571-1581; PMID:21478669; http://dx.doi.org/10.4161/cc.10.10.15612
   PubMed Web of Science ®Google Scholar
• Thurnher M, Gruenbacher G, Nussbaumer O. Regulation of mevalonate metabolism in cancer and immune cells. Biochim Biophys Acta 2013; 1831(6):1009-15; PMID:23524243; http://dx.doi.org/10.1016/j.bbalip.2013.03.003
   PubMed Web of Science ®Google Scholar
• Zhu Y, Casey PJ, Kumar AP, Pervaiz S. Deciphering the signaling networks underlying simvastatin-induced apoptosis in human cancer cells: evidence for non-canonical activation of RhoA and Rac1 GTPases. Cell Death Dis 2013; 4:e568; PMID:23559002; http://dx.doi.org/10.1038/cddis.2013.103
   PubMed Web of Science ®Google Scholar
• Jaiswal M, Dvorsky R, Amin E, Risse SL, Fansa EK, Zhang SC, Taha MS, Gauhar AR, Nakhaei-Rad S, Kordes C, Koessmeier KT, Cirstea IC, Olayioye MA, Haussinger D, Ahmadian MR. Functional cross-talk between ras and rho pathways: a Ras-specific GTPase-activating protein (p120RasGAP) competitively inhibits the RhoGAP activity of deleted in liver cancer (DLC) tumor suppressor by masking the catalytic arginine finger. J Biol Chem 2014; 289(10):6839-49; PMID:24443565; http://dx.doi.org/10.1074/jbc.M113.527655
   PubMed Web of Science ®Google Scholar
• Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005; 5(12):930-42; PMID:16341084; http://dx.doi.org/10.1038/nrc1751
   PubMed Web of Science ®Google Scholar
• Bjarnadottir O, Romero Q, Bendahl PO, Jirstrom K, Ryden L, Loman N, Uhlen M, Johannesson H, Rose C, Grabau D, Borgquist S. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat 2013; 138(2):499-508; PMID:23471651; http://dx.doi.org/10.1007/s10549-013-2473-6
   PubMed Web of Science ®Google Scholar
• Zhang J, Yang Z, Xie L, Xu L, Xu D, Liu X. Statins, autophagy and cancer metastasis. Int J Biochem Cell Biol 2013; 45(3):745-52; PMID:23147595; http://dx.doi.org/10.1016/j.biocel.2012.11.001
   PubMed Web of Science ®Google Scholar
• Roy M, Kung HJ, Ghosh PM. Statins and prostate cancer: role of cholesterol inhibition vs. prevention of small GTP-binding proteins. American Journal of Cancer Research 2011; 1(4):542-561; PMID:21984972
   PubMed Web of Science ®Google Scholar
• Russell RGG, Rogers MJ. Bisphosphonates: From the laboratory to the clinic and back again. Bone 1999; 25(1):97-106; PMID:10423031; http://dx.doi.org/10.1016/S8756-3282(99)00116-7
   PubMed Web of Science ®Google Scholar
• Russell RGG. Bisphosphonates: The first 40 years. Bone 2011; 49(1):2-19; PMID:21555003; http://dx.doi.org/10.1016/j.bone.2011.04.022
   PubMed Web of Science ®Google Scholar
• Coxon JP, Pickering LM, Colston KW. Zoledronic acid inhibits adhesion of breast and prostate cancer cells via inhibition of protein prenylation. Journal of Bone and Mineral Research 2003; 18(7):1359-9
   Web of Science ®Google Scholar
• Coxon JP, Pickering LM, Kirby RS, Colston KW. Zoledronic acid inhibits adhesion of prostate cancer cells to mineralized matrix principally through inhibition of protein geranylgeranylation via a caspase-independent mechanism. Journal of Bone and Mineral Research 2004; 19(9):1598-8
   Web of Science ®Google Scholar
• Eidtmann H, Bundred NJ, DeBoer R, Llombart A, Davidson N, Neven P, Von MG, Miller J, Schenk A, Coleman R. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months follow-up of ZO-FAST. Cancer Res 2009; 69(2):74S-74S
   Web of Science ®Google Scholar
• Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kaessmann H, Piswanger-Soelkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008; 9(9):840-9; PMID:18718815; http://dx.doi.org/10.1016/S1470-2045(08)70204-3
   PubMed Web of Science ®Google Scholar
• Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Postlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, et al. Endocrine Therapy plus Zelodronic Acid in Premenopausal Breast Cancer (vol 360, pg 679, 2009). N Engl J Med 2009; 360(22):2379-2379
   Web of Science ®Google Scholar
• Ben-Aharon I, Vidal L, Rizel S, Yerushalmi R, Shpilberg O, Sulkes A, Stemmer SM. Bisphosphonates in the Adjuvant Setting of Breast Cancer Therapy-Effect on Survival: A Systematic Review and Meta-Analysis. Plos One 2013; 8(8):9; http://dx.doi.org/10.1371/journal.pone.0070044
   Web of Science ®Google Scholar
• Dudakovic A, Tong H, Hohl RJ. Geranylgeranyl diphosphate depletion inhibits breast cancer cell migration. Invest New Drugs 2011; 29(5):912-20; PMID:20480384; http://dx.doi.org/10.1007/s10637-010-9446-y
   PubMed Web of Science ®Google Scholar
• Wasko BM, Dudakovic A, Hohl RJ. Bisphosphonates Induce Autophagy by Depleting Geranylgeranyl Diphosphate. Journal of Pharmacology and Experimental Therapeutics 2011; 337(2):540-6; PMID:21335425; http://dx.doi.org/10.1124/jpet.110.175521
   PubMed Web of Science ®Google Scholar
• Reilly JE, Neighbors JD, Tong H, Henry MD, Hohl RJ. Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis. Clin Exp Metastasis 2015; 32(6):555-66; PMID:26070429; http://dx.doi.org/10.1007/s10585-015-9727-0
   PubMed Web of Science ®Google Scholar
• Shevrin DH, Gorny KI, Kukreja SC. Patterns of metastasis by the human-prostate cancer cell-line PC-3 in athymic nude-mice. Prostate 1989; 15(2):187-94; PMID:2529482; http://dx.doi.org/10.1002/pros.2990150212
   PubMed Web of Science ®Google Scholar
• Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, Mundy GR, Yoneda T. Bisphosphonate risedronate reduces metastatic human breast-cancer burden in bone in nude-mice. Cancer Research 1995; 55(16):3551-7; PMID:7627963
   PubMed Web of Science ®Google Scholar
• Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T. Use of bisphosphonates for the treatment of bone metastasis in experimental animal models. Cancer Treatment Reviews 1999; 25(5):293-9; PMID:10544073; http://dx.doi.org/10.1053/ctrv.1999.0133
   PubMed Web of Science ®Google Scholar
• Kostenuik PJ, Orr FW, Suyama K, Singh G. Increased growth-rate and tumor burden of spontaneously metastatic walker-256 cancer-cells in the skeleton of bisphosphonate-treated rats. Cancer Research 1993; 53(22):5452-7; PMID:8221685
   PubMed Web of Science ®Google Scholar
• Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro nd inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. Journal of Pharmacology and Experimental Therapeutics 2001; 296(2):235-42; PMID:11160603
   PubMed Web of Science ®Google Scholar
• Hancock JF, Magee AI, Childs JE, Marshall CJ. ALL RAS PROTEINS ARE POLYISOPRENYLATED BUT ONLY SOME ARE PALMITOYLATED. Cell 1989; 57(7):1167-77; PMID:2661017; http://dx.doi.org/10.1016/0092-8674(89)90054-8
   PubMed Web of Science ®Google Scholar
• Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. Measurement of Protein Using Bicinchoninic Acid. Analytical Biochemistry 1985; 150(1):76-85; PMID:3843705; http://dx.doi.org/10.1016/0003-2697(85)90442-7
   PubMed Web of Science ®Google Scholar